Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

BACKGROUND: Docetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for Health and Clinical Excellence (NICE) preli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zhong, Lixian, Pon, Vickie, Srinivas, Sandy, Nguyen, Nicole, Frear, Meghan, Kwon, Sherry, Gong, Cynthia, Malmstrom, Robert, Wilson, Leslie
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3661482/
https://ncbi.nlm.nih.gov/pubmed/23717582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0064275
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars